What Cost-Effectiveness Actually Means
What Cost-Effectiveness Actually Means
In pharmacoeconomics, cost-effectiveness typically answers a specific question:
How much health benefit do we gain per dollar spent compared to the alternative?
Often, this is expressed as cost per quality-adjusted life year (QALY). If a therapy produces better outcomes at a reasonable incremental cost relative to a comparator, it may be deemed “cost-effective.”
That determination is usually modeled over a long time horizon — sometimes decades, sometimes a lifetime.
From an academic standpoint, this makes sense. Chronic disease unfolds over years. Prevented strokes and avoided dialysis matter over the long run.
But that modeling framework does not answer a simpler, more immediate question:
Can we actually pay for this — right now?
A Therapy Can Be Cost-Effective and Still Financially Crushing
Imagine two drugs:
Drug A costs $5,000 per year.
Drug B costs $20,000 per year but prevents costly complications down the road.
A cost-effectiveness model may show Drug B is the better value over 20 years. Fewer hospitalizations. Fewer complications. Better survival.
On paper, Drug B “wins.”
But if a patient faces a 20% coinsurance, that’s $4,000 out of pocket annually.
For many households, that is not just inconvenient — it is impossible.
Likewise, if a payer covers thousands of eligible patients simultaneously, the short-term budget impact may be enormous, even if lifetime projections suggest savings.
Cost-effectiveness measures efficiency.
Affordability measures cash flow reality.
They operate on different timelines.
The GLP-1 and Hepatitis C Example
We’ve seen this disconnect play out in real time.
When direct-acting antivirals for hepatitis C, such as Sovaldi, entered the market, they were clinically transformative. Cure rates exceeded 90%. From a lifetime perspective, curing hepatitis C avoided cirrhosis, hepatocellular carcinoma, transplant, and death.
They were widely considered cost-effective.
But if every eligible patient had been treated immediately at launch prices, state Medicaid programs and private payers would have experienced severe budget shocks.
The therapy was economically rational.
It was not immediately affordable at scale.
We are seeing a similar debate unfold with GLP-1–based therapies such as Wegovy and Mounjaro.
If long-term cardiovascular outcome data continue to show reductions in myocardial infarction, stroke, and kidney disease, these therapies may prove cost-effective over decades.
But obesity affects tens of millions of people. Even if only a fraction initiate therapy, the aggregate short-term spending impact is staggering.
A therapy can be cost-effective and still overwhelm annual pharmacy budgets.
Those two truths can coexist.
The Patient-Level Reality
From a patient’s perspective, cost-effectiveness modeling may feel abstract.
If a therapy is “worth it” over 20 years but requires thousands of dollars annually out of pocket, many patients will never realize that projected benefit.
Economic models discount future costs and benefits. Patients live month to month.
Even modest copayments can reduce adherence. High deductibles can delay initiation. Coinsurance tied to list price can make even “value-based” drugs inaccessible.
In other words:
A therapy may maximize societal value
while remaining financially inaccessible to the individual.
That is not a modeling flaw — it is a financing problem.
The Payer and System Perspective
For payers, the tension is slightly different.
Cost-effectiveness analyses often use lifetime horizons. But commercial insurance contracts are annual. Employers reassess plans yearly. Members switch insurers.
If a private insurer pays today for prevention that reduces stroke risk 15 years from now, there is no guarantee they will still cover that member when the savings materialize.
The benefit may accrue to a competitor — or to Medicare.
This misalignment weakens incentives to invest aggressively in long-term health, even when models suggest it is economically sound.
Again, the therapy may be cost-effective.
The investment may not be financially recoverable for the payer making it.
Budget Impact vs. Value
One of the recurring themes in my graduate work — and in the papers posted at FredPharmD.com — is the distinction between:
Cost-effectiveness analysis (CEA)
Budget impact analysis (BIA)
CEA answers: Is this a good value compared to alternatives?
BIA answers: What happens to the budget next year if we adopt this?
A drug can pass a cost-effectiveness threshold and still fail a budget impact threshold.
This is not hypocrisy. It is math operating on different scales and timelines.
But when policymakers conflate the two, public discourse suffers.
Declaring a therapy “cost-effective” does not magically produce liquidity.
Declaring it “unaffordable” does not negate its long-term value.
Why This Distinction Matters More Than Ever
As high-cost therapies expand — gene therapies, specialty biologics, GLP-1s — this gap between value and affordability will grow.
The healthcare system is increasingly capable of producing interventions that:
Dramatically improve outcomes
Shift disease trajectories
Reduce lifetime costs
But those same interventions may:
Require massive upfront investment
Concentrate spending in short timeframes
Strain annual budgets
The policy challenge is not deciding whether value matters.
It is designing financing mechanisms that allow high-value care without destabilizing the system.
A More Honest Conversation
When discussing new therapies, we should be explicit:
Is it cost-effective?
Is it affordable at scale?
Over what time horizon?
For whom?
Patients, payers, and policymakers deserve clarity.
Calling something cost-effective is not the end of the discussion — it is the beginning.
Affordability is a separate, equally important question.
Until we treat it that way, we will continue to see the same cycle:
Breakthrough innovation.
Sticker shock.
Access restrictions.
Public backlash.
And a healthcare system caught between long-term value and short-term financial constraint.
Cost-effectiveness tells us whether something is worth it.
Affordability tells us whether we can actually do it.
Those are not the same thing — and pretending they are makes policy harder than it needs to be.
